Tag: chemistry
-
Generative A.I. Designs Novel Synthetic Proteins
Generate:Biomedicines describes its Chroma generative A.I. model in yesterday’s issue of the journal Nature, and is making the model available as open source through GitHub.
-
Cannabinoid Shown Safe, Lowers Agitation in Alzheimer’s Patients
A clinical trial in a small group of participants suggests a cannabinoid drug is safe and well-tolerated, and reduces agitation among patients with Alzheimer’s disease.
-
Start-Up Developing Precision Antibiotics for Resistant Bacteria
A company formed earlier this year is developing precision treatments for bacteria resistant to conventional antibiotics, and raising £4.3 million ($US 5.4 million) in seed funds.
-
Peanut Allergy Toothpaste Shown Safe in Trial
Results of a clinical trial show a peanut allergy treatment formulated as a toothpaste can safely deliver immunotherapy to raise recipients’ peanut tolerance.
-
Merger to Form Programmable Nano-Medicines Company
A life science venture investor is merging two of its biotechnology portfolio companies to form a single developer of nanoscale medications with programmable properties.
-
Start-Up Adapts Crispr for Molecular Detection, Raises $40M
A new company is underway that says it adapts the gene editing technique Crispr to make detecting nucleic acid targets like DNA or RNA faster and simpler.
-
High-Speed Biologic Injection Device Shown Feasible
A developer of an auto-injection technology says its device can deliver a biologic drug under the skin in a fraction of the time of conventional syringes.
-
Longevity Science Group Spins-Off Biotech Start-Up
An organization funding research on extending the human life span by preventing age-related diseases is founding its first biotechnology company.
-
Neuro Disease Biotech Gains $61M in Early Funds
A developer of treatments for Alzheimer’s disease that seeks to improve the condition of the brain’s support cells is raising £48 million ($US 61 million) in its first venture round.
-
NIH Funds Antibody Discovery for Difficult Protein Targets
A biotechnology company is receiving NIH support for discovering antibodies that address the vast majority of proteins coded by the human genome, passed-up so far by drug makers.